Articles tagged "Heart/lung transplantation"

2022 American Transplant Congress
Perioperative IL-6 Blockade Promotes Intra-Graft Regulation and Prevents Costimulation-Blockade Resistant Rejection
M. Muckenhuber¹, K. Mengrelis¹, A. M. Weijler¹, V. Kainz¹, R. Steiner¹, H. Regele², T. Wekerle¹
¹Dept. of General Surgery, Div. of Transplantation, Medical University of Vienna, Vienna, Austria, ²Dept. of Pathology, Medical University of Vienna, Vienna, Austria
*Purpose: Our group has recently shown that CTLA4-Ig monotherapy leads to limited murine heart allograft survival associated with decreased Treg frequencies and early acute T-cell…
2022 American Transplant Congress
Presence of Infiltrating Regulatory T Cells in the Cardiac Xenografts and Their Potential Role in Graft Survival
A. K. Singh¹, C. E. Goerlich¹, G. Braileanu¹, A. Hershfeld¹, T. Zhang¹, I. Tatarov¹, B. Lewis¹, F. Sentz¹, D. Ayares², B. Griffith¹, M. M. Mohiuddin¹
¹Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, ²Revivicor Inc, Blacksburg, WV
*Purpose: Regulatory T (CD4+CD25HiFoxP3+) cells (Treg) are a very small subset of CD4+ T cells that have been shown to play an important role in…
2022 American Transplant Congress
Current State of Use of Hepatitis C Viremic Donor Organs in Negative Recipients in the United States: A National Survey
K. Ryland¹, K. Hattori², J. Steinbrink³, N. Theodoropoulos⁴, M. Ison⁵
¹Mayo Clinic, Jacksonville, FL, ²Duke university hospital, Durham, NC, ³Duke University, Durham, NC, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Northwestern University Comprehensive Transplant Center, Chicago, IL
*Purpose: Since the advent of direct-acting antiviral (DAA) therapy, use of hepatitis C (HCV) viremic donor organs in HCV negative recipients has become more common.…
2021 American Transplant Congress
Pilot Study for the Use of Shortened Preemptive Therapy with Glecaprevir/pibrentasvir (g/p) and Ezetimibe in Hepatitis C Seronegative Solid Organ Transplant Recipients (Kidney and Heart) of Hepatitis C Viremic Donors
B. Aqel¹, H. Khamash², A. Moss³, D. E. Steidley⁴, R. C. Dickson¹
¹Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ, ²Nephrology and Hypertension, Mayo Clinic, Phoenix, AZ, ³Transplant Surgery, Mayo Clinic, Phoenix, AZ, ⁴Cardiology, Mayo Clinic, Phoenix, AZ
*Purpose: This prospective study aims to assess the efficacy of preemptive therapy with eight days of a combination of direct-acting antivirals (DAAs) (Mavyret) (Pibrentasvir /Glecaprevir)…
2021 American Transplant Congress
Inhibition of Fatty Acid Beta-Oxidation Prolongs Heart Allograft Survival
B. W. Wong, Y. Zhu, H. Dun, L. Ye
Surgery, Washington University School of Medicine, Saint Louis, MO
*Purpose: To test the therapeutic efficacy of pharmacological inhibition of fatty acid beta-oxidation (FAO) on acute heart allograft survival.*Methods: We used a heterotopic Balb/c donor…
2021 American Transplant Congress
A Novel Mouse Model of Cardiac Allograft Vasculopathy
H. Tsuda¹, E. Reed², W. Baldwin¹, R. Fairchild¹
¹Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, ²Pathology and Laboratory Medicine, University of California, Los Angeles, CA
*Purpose: Cardiac allograft vasculopathy (CAV) is a major long-term complication of heart transplantation and the presence of donor specific antibodies (DSA) is associated with an…
2021 American Transplant Congress
Novel Morphologic Biomarkers of Cardiac Allograft Remodeling are Associated with Multiple Peri- and Post-transplant Inflammatory Processes
C. Yuan¹, S. Arabyarmohammadi¹, H. Li¹, E. Peyster², P. Lal³, M. Feldman³, K. Margulies², A. Madabhushi¹
¹Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, ²Cardiovascular Research Institute, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA
*Purpose: It has long been recognized that transplanted hearts develop a stiffened, restrictive physiology at an accelerated rate compared to native hearts. While this is…
2021 American Transplant Congress
Anti-CD272 Antibody (6B2) Generated Foxp3⁺Regulatory T Cells and Suppressed Donor Specific Antibody in Murine Cardiac Transplant Model
Y. Yamamoto¹, M. Uchiyama², K. Uchida³, H. Yagita³, M. Niimi¹
¹Department of Surgery, Teikyo University, Tokyo, Japan, ²Department of Cardiovascular Surgery, Teikyo University, Tokyo, Japan, ³Juntendo University, Tokyo, Japan
*Purpose: The co-inhibitory receptor B and T lymphocyte attenuator (BTLA; CD272) has been implicated in the regulation of autoimmune and may potentially play an important…
2021 American Transplant Congress
Cold Perfusion for Ischemia Minimization Reduces Cardiac Injury in an Ex Vivo Xenoperfusion Model
M. R. Connolly¹, A. Calhoun¹, F. Pollok¹, L. Burdorf¹, Z. Habibabady¹, M. Ma¹, S. Miura¹, W. Eyestone², C. Phelps², D. Ayares²
¹Massachusetts General Hospital, Boston, MA, ²Revivicor, Blacksburg, VA
*Purpose: Prior studies using Steen’s cold perfusion storage technique for heart ischemia minimization (IM) prevented initial xenograft dysfunction (IXD). Our pilot data evaluates the effect…
2021 American Transplant Congress
Impact of New Onset Diabetes After Transplantation on Heart Transplant Recipients
W. Kang¹, W. Keattiyoat², M. Kim¹, C. Bhardwaj²
¹Department of Internal Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, ²Department of Cardiology, University of Illinois College of Medicine at Peoria, Peoria, IL
*Purpose: The purpose of this study is to investigate New Onset Diabetes After Transplantation (NODAT) incidence and its impact on post-transplant prognosis in adult heart…